Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker (Nasdaq: BRKR) reported Q4-25 revenue of $977.2M (flat yoy; -5.1% organic) and FY25 revenue of $3.44B (+2.1% reported; -3.7% organic). FY25 GAAP loss per share was $(0.15); non-GAAP EPS was $1.83. Bruker guided FY26 revenue to $3.57–3.60B and non-GAAP EPS to $2.10–2.15, noting an ~8% FX headwind to EPS and planned cost savings to expand margins.
Bruker (NYSE:BRKR) launched iNTApharma, a label-free, native-state nanoparticle characterization platform with single-particle sensitivity for viral vectors, LNPs, lentiviral vectors, and extracellular vesicles.
Optimized for particles 50–300 nm, it provides rapid size and concentration measurements, automated well‑plate acquisition, and will be placed with early-access partners in H1 2026 with broader commercial availability in H2 2026.
Chemspeed and SciY (Nasdaq: BRKR) unveiled an open Self‑Driving Lab (SDL) platform on February 9, 2026 at SLAS2026 to unify lab automation, analytics and AI orchestration.
The SDL offers vendor‑agnostic integration of modular precision automation, NMR/IR/MS/X‑ray analytics, and an AI‑ready FAIR data backbone to enable autonomous, 24/7 DMTA workflows and scalable QC/R&D operations.
Bruker (Nasdaq: BRKR, BRKRP) announced a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend will be paid on March 2, 2026 to holders of record as of February 15, 2026.
Bruker (Nasdaq: BRKR) will report fourth quarter and fiscal 2025 results before market open on Thursday, February 12, 2026, and will host a conference call and webcast at 8:30 a.m. Eastern Standard Time.
The webcast will be available at the company investor site under “Q4 2025 Earnings Webcast,” with a referenced slide presentation posted shortly before the call. Investors may join by phone or pre-register for a personalized dial-in and PIN. A telephone replay will be available starting one hour after the call through March 12, 2026.
Bruker (Nasdaq: BRKR) BEST division announced two multi-year supply agreements with two global healthcare OEMs totaling approximately $500 million in expected future BEST revenues, with one agreement extending up to seven years. The expanded framework agreements cover delivery of Bruker’s high-performance niobium-titanium-copper composite superconductors for next-generation MRI magnets, primarily to production sites in the United States and United Kingdom. Bruker said its superconductors support novel helium-free MRI magnet architectures and meet demanding field stability and homogeneity requirements while leveraging manufacturing sites in Europe and the US.
Bruker (NASDAQ: BRKR) acquired an additional 60% of TOFWERK AG, consolidating ownership to 100% and expanding Bruker’s mass spectrometry portfolio into applied small‑molecule markets. TOFWERK, based in Thun, Switzerland, is profitable, employs 130 people, has >b>1,000 instruments worldwide, and reported 2025 revenue of ~$40 million. TOFWERK will operate as a distinct brand, preserving Swiss R&D and OEM partnerships; financial terms were not disclosed.
Bruker Corporation (Nasdaq: BRKR) will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on Monday, January 12, 2026 at 9:00 AM Pacific Time. A live audio webcast will be available on the company's Investor Relations website and a replay will be posted in the Events & Presentations section and remain available for 30 days after the presentation.
RI Research Instruments (BRKR) announced approximately €35 million of orders to supply key components and enabling subsystems for the gamma-ray source at ELI-NP in Romania, with major deliveries expected in late 2026. The scope covers expansion of an existing linac, beam-guiding and focusing components, a linac upgrade to increase pulse rate by 200x, and an optical resonator that amplifies the laser by more than 900x developed with LICOS (TUM spin-out).
The system will produce high-flux, monochromatic, energy-tunable gamma rays (1–20 MeV) via inverse Compton scattering to support advanced nuclear and fundamental research.
Bruker (Nasdaq: BRKR) announced approximately $25 million of orders for high-performance magnetic resonance systems from three European research institutions, with revenue recognition expected over fiscal 2026 and 2027.
Orders include a novel NMR relaxometry system for École Normale Supérieure (ENS-PSL) to complement a 900 MHz spectrometer, two 800 MHz and one 100 MHz systems plus an E580 EPR spectrometer for Max Planck Institute for Solid-State Research focused on battery materials, and an ultra-high field 1 GHz NMR system for Institut Européen de Chimie et Biologie (IECB) as Bordeaux’s flagship platform. Separately, a second 1.2 GHz NMR system was accepted at the University of Birmingham in Q4 2025.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
